ImpediMed (ASX:IPD) subsidiary, ImpediMed, secured a five-year $15 million growth capital facility with US-based specialist finance company SWK Funding, according to a Thursday filing with the Australian bourse.
The facility will be used for growth and commercialization activities, with $10 million available immediately in tranche one and $5 million available in tranche two if the company meets sales targets for the current fiscal year and decides to draw on the facility, the filing said.
ImpediMed shares rose 3% in afternoon trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.